
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Liedtke, Hematologist in Stanford, CA?
Dr. Michaela Liedtke, MD is a Hematologist, who primarily practices in Stanford, CA with 1 additional practice location. She is board certified. Dr. Liedtke graduated from Medizinische Hochschule Hannover and completed her residency at Albert Einstein College of Medicine. Dr. Liedtke is fluent in English and German, and is currently seeing new patients. Dr. Liedtke’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Liedtke’s office at (650) 723-4000.
Where did Dr. Liedtke go to medical school and complete their residency?
Fellowship: Stanford University Medical Center CA | Memorial Sloan-Kettering Cancer Center NY | Stanford University Medical Center CA | Memorial Sloan-Kettering Cancer Center NY | Stanford University Medical Center, Stanford Ca - Bariatric Surgery
Residency: Albert Einstein College of Medicine | Albert Einstein College of Medicine Affiliated Hospitals
Medical School: Medizinische Hochschule Hannover | Hannover Medical School
Is Dr. Liedtke board certified as a Hematologist?
Yes, Dr. Michaela Liedtke, MD is board certified by the American Board of Internal Medicine since 2006, American Board of Internal Medicine since 2005
What languages does Dr. Liedtke speak?
Dr. Liedtke and their clinical team can communicate with patients in the following languages:
English
German
What conditions does a Hematologist like Dr. Liedtke typically treat?
As a Hematologist, Dr. Liedtke diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Liedtke. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Multiple Myeloma
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
- Active multiple myeloma
- Untreated multiple myeloma
- Plasma cell myeloma
ICD-10 Codes:
- C9000: Multiple myeloma not having achieved remission
Also known as:
- Light Chain Amyloidosis
- Amyloidosis
- AL Amyloidosis
- Primary Amyloidosis
- Immunoglobulin Light Chain Amyloidosis
ICD-10 Codes:
- E8581: Light chain (AL) amyloidosis
Also known as:
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia
- ALL
- Acute lymphocytic leukemia
- Lymphoblastic leukemia
ICD-10 Codes:
- C9100: Acute lymphoblastic leukemia not having achieved remission
Also known as:
- Monoclonal Gammopathy
- Blood Disorder
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ)
- MGUS
- Plasma Cell Disorder
- Gammopathy of Undetermined Significance
ICD-10 Codes:
- D472: Monoclonal gammopathy
What procedures does a Hematologist like Dr. Liedtke typically perform?
As a Hematologist, Dr. Liedtke performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Liedtke. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Bone Marrow Biopsy and Aspiration
- Bone Marrow Aspiration
- Biopsy
- Bone Marrow Tests
- Bone Marrow Exam
- Bone Marrow Sample Collection
- Diagnostic Bone Marrow Procedure
- Bone Marrow Biopsy
- Marrow Aspiration
- Diagnostic Bone Marrow Test
- Bone Marrow Sample
CPT Codes:
- 38222: Diagnostic bone marrow; biopsy(ies) and aspiration(s)
- 38220: Diagnostic bone marrow; aspiration(s)
Also known as:
- Lung Diffusing Capacity Test
- DLCO Test
- Carbon Monoxide Diffusing Capacity
- Lung Gas Exchange Test
CPT Codes:
- 94729: Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)
Also known as:
- Blood Transfusion
- Blood Transfusion and Donation
- Blood product transfusion
- Red blood cell transfusion
- Plasma transfusion
CPT Codes:
- 36430: Transfusion, blood or blood components
Also known as:
- Declotting of Vascular Access Device
- Catheter declotting
- Thrombolytic therapy for catheter
- Blocked port-a-cath treatment
- Vascular access device unblocking
CPT Codes:
- 36593: Declotting by thrombolytic agent of implanted vascular access device or catheter
Also known as:
- PICC Line Insertion (Adult/Older Child)
- Peripherally Inserted Central Catheter
- PICC Line Placement
- Central Venous Catheter Insertion
CPT Codes:
- 36573: Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older
Also known as:
- Guided Lumbar Puncture
- Guided Spinal Tap
- Diagnostic Lumbar Puncture with Imaging
- CT Guided Spinal Tap
- Fluoroscopy Guided Lumbar Puncture
CPT Codes:
- 62328: Spinal puncture, lumbar, diagnostic; with fluoroscopic or CT guidance
Also known as:
- Lumbar Puncture (Spinal Tap)
- Cerebrospinal Fluid (CSF) Analysis
- Spinal tap
- CSF analysis
- Diagnostic lumbar puncture
- Cerebrospinal fluid collection
CPT Codes:
- 62270: Spinal puncture, lumbar, diagnostic;
Does Dr. Liedtke accept my insurance?
Dr. Liedtke accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Liedtke accept in Stanford, CA?
Dr. Liedtke in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Medicaid
Medicare
Santa Cruz County
State of California
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Liedtke's office located?
Recognitions
Awards
Doris Duke Foundation
Translational Research Award
ASCO
Young Investigator Award
Research grant, Hope Street Kids Foundation
Methods in Clinical Cancer Research Scholar, ASCO/AACR
Lymphoma Research Foundation
Fellowship Award
Stanford Department of Medicine
Translational Research Award
Publications
A single-center experience of the tionwide daunorubicin shortage
, 2013
Lelidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain
, 2013
AG10 inhibits amyloidogenesis
, 2013
The prognostic value of diagnosing concurrent multiple myeloma
, 2013
Sequential azacitidine plus lelidomide combition
, 2013
Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines
, 2013
Absolute lymphocyte count at day 28 independently predicts event-free
, 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lelidomide for
, 2012
Heart transplantation and cardiac amyloidosis: Approach to screening and novel magement strategies
, 2012
Hemophagocytic lymphohistiocytosis in pregncy: A case report and review of treatment options.
Phase I trial of a novel human monoclol antibody mAb216 in patients with relapsed or refractory B
, 2012
A Phase I Study of Sequential Azacitidine
, 2010
Second-line mitoxantrone, etoposide
, 2010
Plasma cell leukemia: concepts and magement.
, 2010
Surveillance imaging during remission identifies a group of patients with more favorable aggressive
, 2006
Regulation of Bcr-Abl-induced SAP kise activity
, 1998
Effects of serum and plasma matrices on multiplex immunoassays.
, 2014
Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
, 2014
A single-center experience of the nationwide daunorubicin shortage
, 2013
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light
, 2013
AG10 inhibits amyloidogenesis
, 2013
The prognostic value of diagnosing concurrent multiple myeloma
, 2013
Sequential azacitidine plus lenalidomide combination
, 2013
Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines
, 2013
Amrubicin, a Novel Investigational Anthracycline
A Phase I/II Study of Bortezomib
Absolute lymphocyte count at day 28 independently predicts event-free
, 2012
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide
, 2012
More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis
, 2012
Heart transplantation and cardiac amyloidosis
, 2012
Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options.
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B
, 2012
The Transcription Factor Encyclopedia
, 2012
A Phase I Study of Sequential Azacitidine
, 2010
Temozolomide In Acute Myeloid Leukemia
, 2010
Second-line mitoxantrone, etoposide
, 2010
Plasma cell leukemia: concepts and management.
, 2010
Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential
, 2010
Therapeutic targeting of MLL
, 2009
Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
, 2008
Surveillance imaging during remission identifies a group of patients with more favorable aggressive
, 2006
Regulation of Bcr-Abl-induced SAP kinase activity
, 1998
A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO
, 1992